Page 111 - MEMORIA_SEHH-FEHH_2023

MEMORIA ANUAL 2023
SOCIEDAD ESPAÑOLA DE
HEMATOLOGÍA Y HEMOTERAPIA
PETHEMA
FUNDACIÓN ESPAÑOLA DE
HEMATOLOGÍA Y HEMOTERAPIA
• Comprehensive Characterization of the Bone Marrow Microenvironment Transcrip-
tional Remodeling in the Progression from MGUS to Smoldering and Multiple My-
eloma.
65th American Society of Hematology Annual Meeting and Exposition 2023 (ASH 2023).
09-12 Dec 2023, San Diego, CA, USA. Blood. 2023;142(Supplement 1):88. https://doi.
org/10.1182/blood-2023-178534.
Cenzano I, Cocera M, Bantan A, Larrayoz M, Vilas-Zornoza A, San-Martín P, Aguirre-Ruiz P,
Ariceta B, Ye Y, Alignani D, López A, Kurowska A, AlSultan F, Shuwaikan R, Lagani V, Teg-
ner J, Martín Subero II, Martínez-Climent JA, Agirre X, Sáez-Ochoa B, Paiva B, San-Miguel
J, Hernáez M, Calvo IA, Gómez-Cabrero D, Prósper F.
• Sequential Scmultiomics of In Vivo CAR-T Cells Allows Characterization of Tran-
scriptional Differences between Patients, and Identifies IL10 As a Potential Mecha-
nism of Resistance to CAR-T Cells in MM.
65th ASH Annual Meeting and Exposition 2023 (ASH 2023). 09-12 Dec 2023, San Diego,
CA, USA. Blood. 2023;142(Supplement 1):3433. https://doi.org/10.1182/blood-2023-182887.
Rodríguez-Madoz JR, Jordana-Urriza L, Serrano G, Oliver-Caldes A, Calleja-Cervantes
ME, San-Martín P, Vilas-Zornoza A, Ullate-Agote A, Zabaleta A, Alignani D, Lozano T, Ca-
bañas Perianes V, Reguera JL, Navarro-Bailón A, Español-Rego M, Pascal M, Moraleda
JM, Pérez-Simón JA, Mateos MV, Sánchez-Guijo Martín F, Urbano-Ispizua A, Juan M, Al-
fonso Piérola A, Rifón JJ, Rodríguez Otero P, Paiva B, Inogés S, López-Díaz de Cerio A,
Lasarte JJ, San Miguel J, Fernández de Larrea C, Hernáez M, Prósper F.
• Kinetics and Biology of Circulating Tumor Cells (CTCs) and Measurable Residual
Disease (MRD): Two Dynamic High-Risk Clones in Multiple Myeloma (MM).
65th ASH Annual Meeting and Exposition 2023 (ASH 2023). 09-12 Dec 2023, San Diego,
CA, USA. Blood. 2023;142(Supplement 1):871. https://doi.org/10.1182/blood-2023-185661.
Guerrero C, Termini R, Garcés JJ, Calasanz MJ, Ríos R, Cabezudo E, Rosiñol L, Bargay J,
Pérez-Montaña A, Oriol Rocafiguera A, Cabañas Perianes V, Nájera MJ, González García
E, Ocio EM, Sureda Balari AM, De Arriba F, Hernández García MT, García A, Martínez-
López J, Blanchard MJ, González Pérez MS, Iglesias R, Orfao A, Mateos MV, Lahuerta
Palacios JJ, Bladé J, San-Miguel J, Cedena MT, Puig N, Paiva B.
• Clinical Significance of Measurable Residual Disease (MRD) in Relapsed/Refracto-
ry Multiple Myeloma (RRMM) Patients (Pts) Treated with Chimeric Antigen Receptor
(CAR) T Cells and T-Cell Engagers (TCE).
65th ASH Annual Meeting and Exposition 2023 (ASH 2023). 09-12 Dec 2023,
San Diego, CA, USA. Blood. 2023;142(Supplement 1):94. https://doi.org/10.1182/
blood-2023-185980.
111